- Clinical Trials
- Research News
- Industry Trends
- Agency Actions
- Drug Safety Issues
- Approvals, Launches, & New Indications
- Health Care Reform
Noxafil Delayed-Release Tablets Approved
New formulation for prevention of Aspergillus and Candida infections (November 26)
A new formulation for posaconazole (Noxafil, Merck) 100 mg delayed-release tablets has been approved. Patients take a loading dose of 300 mg (three 100-mg delayed-release tablets) twice daily on the first day, followed by a once-daily maintenance dose of 300 mg (three 100-mg delayed-release tablets) starting on the second day of therapy.
Merck also sells a 40-mg/mL oral suspension, which is taken three times daily.
The delayed-release tablets and oral suspension are indicated for the prophylaxis of invasive Aspergillus and Candida infections in patients 13 years of age and older with a severely compromised immune system, such as hematopoietic stem-cell transplant recipients with graft-versus-host disease or those with hematological malignancies with prolonged neutropenia resulting from chemotherapy.
Posaconazole delayed-release tablets and the oral suspension are not to be used interchangeably because of differences in the dosing of each formulation.[Source: Merck; November 26, 2013.]